Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises on MicroTech Medical US$249 million Hong Kong IPO

  • en
  • zh
  • Language options

19 October 2021

Clifford Chance advises on MicroTech Medical US$249 million Hong Kong IPO

Leading international law firm Clifford Chance has advised the joint sponsors Goldman Sachs and China International Capital Corporation on MicroTech Medical's US$249 million (HK$1.94 billion) initial public offering (IPO) on the mainboard of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. The Hangzhou-based firm offers diabetes therapy and manufactures medical devices to improve diabetes management globally. Besides its home country, MicroTech Medical's flagship product – the equal patch insulin pump system (Equil) – is sold to over 20 countries across Europe, Asia Pacific, the Middle East, Africa and Latin America.

The deal was jointly led by partners Fang Liu and Virginia Lee, supported by counsel Chen Sheng, associates Chen Hongzhou, Jiao Luyi, Fan Yumeng and Yang Tao.

Partner Fang Liu commented, "We are very proud to support on the MicroTech Medical's IPO, our third medical device company HK listing since the middle of this year, following Zylox-Tonbridge's in July and Angelalign's in June."

高伟绅助力微泰医疗2.49亿美元首次公开发行和香港上市

国际领先律师事务所高伟绅就微泰医疗器械(“微泰医疗”)2.49亿美元(约19.4亿港币)按照上市规则18A章首次公开发行和香港联交所主板上市,为联席保荐人高盛和中金公司提供法律服务。微泰医疗是一家总部位于杭州的糖尿病科技公司,致力于提供糖尿病治疗和医疗器械生产,以改善全球糖尿病管理模式。微泰医疗的旗舰产品Equil(贴敷式胰岛素泵)不仅在国内出售,更是销往欧洲、亚太、中东、非洲和拉丁美洲的 20 多个国家。

本项目由合伙人方刘和李婉雯共同牵头,团队成员包括陈盛、杨弢、陈虹州、焦露漪和范雨萌。

方刘律师表示:“我们非常荣幸参与微泰医疗上市,这是年中以来继时代天使及归创通桥后我们第三个医疗器械公司香港上市项目。 ”